News
An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a phase 1 clinical trial has shown.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results